Gritstone Bio Inc
GRTS
Market Cap$81.06M
Close$
$-0.54
167.9% downside
Current Fair Value
167.9% downsideOvervalued by 167.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $81.06 Million |
|---|---|
| Enterprise Value | $138.04 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-1.24 |
| Beta | 1.83 |
| Outstanding Shares | 108,569,374 |
| Avg 30 Day Volume | 2,302,449 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.56 |
|---|---|
| PEG | -2.97 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 8.82 |
| Enterprise Value to EBIT | -0.95 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.75 |
| Debt to Equity | 7.4 |
Revenue Sources
No data
ESG Score
No data
About Gritstone Oncology Inc
CEO: Andrew Allen